From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC

Autor:	Sai-Hong Ignatius Ou, Alexandria T.M. Lee, Misako Nagasaka
Rok vydání:	2023
Předmět:	Oncology Hematology
Zdroj:	Critical Reviews in Oncology/Hematology. 187:104019
ISSN:	1040-8428
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0f5142da8883032a59804236940358a1 https://doi.org/10.1016/j.critrevonc.2023.104019 Zobrazit plný text záznamu Full Text from ScienceDirect